GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (NAS:RLMD) » Definitions » PE Ratio (TTM)

RLMD (Relmada Therapeutics) PE Ratio (TTM) : At Loss (As of Dec. 14, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Relmada Therapeutics PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-12-14), Relmada Therapeutics's share price is $0.367. Relmada Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.86. Therefore, Relmada Therapeutics's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Relmada Therapeutics's PE Ratio (TTM) or its related term are showing as below:

RLMD' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



RLMD's PE Ratio (TTM) is ranked worse than
100% of 246 companies
in the Biotechnology industry
Industry Median: 27.14 vs RLMD: At Loss

Relmada Therapeutics's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-0.72. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.86.

As of today (2024-12-14), Relmada Therapeutics's share price is $0.367. Relmada Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.89. Therefore, Relmada Therapeutics's PE Ratio without NRI for today is At Loss.

Relmada Therapeutics's EPS without NRI for the three months ended in Sep. 2024 was $-0.73. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.89.

During the past 3 years, the average EPS without NRI Growth Rate was 4.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was -13.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was -57.00% per year.

During the past 11 years, Relmada Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 27.30% per year. The lowest was -785.80% per year. And the median was -26.05% per year.

Relmada Therapeutics's EPS (Basic) for the three months ended in Sep. 2024 was $-0.72. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.86.


Relmada Therapeutics PE Ratio (TTM) Historical Data

The historical data trend for Relmada Therapeutics's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics PE Ratio (TTM) Chart

Relmada Therapeutics Annual Data
Trend Aug13 Jun15 Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Relmada Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Relmada Therapeutics's PE Ratio (TTM)

For the Biotechnology subindustry, Relmada Therapeutics's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relmada Therapeutics's PE Ratio (TTM) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Relmada Therapeutics's PE Ratio (TTM) falls into.



Relmada Therapeutics PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Relmada Therapeutics's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=0.367/-2.860
=At Loss

Relmada Therapeutics's Share Price of today is $0.367.
Relmada Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.86.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Relmada Therapeutics  (NAS:RLMD) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Relmada Therapeutics PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Relmada Therapeutics Business Description

Traded in Other Exchanges
Address
2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Executives
Sergio Traversa director, officer: Chief Executive Officer 138 CANTERBURY LN, BLUE BELL PA 19422
Maged Shenouda director 305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Paul Edward Kelly director 300 EAST 56TH STREET, APT 19E, NEW YORK, NY 10022
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
Chuck Ence officer: Chief Financial Officer 3000 S. UNIVERSITY BLVD., DENVER CO 80210
Cedric O'gorman officer: Chief Medical Officer C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Fabiana Fedeli director C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Thomas Wessel officer: EVP, Head of R&D 15 SKYLINE DRIVE, HAWTHORNE NY 10532
Eric Thomas Schmidt director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John Glasspool director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Ottavio V. Vitolo officer: Chief Medical Officer 71 WESTLAND AVENUE, NEWTON MA 02465
Shreeram Agharkar director P.O BOX 2042, PRINCETON NJ 08543
Sandesh Seth director 300 E 93RD STREET, #20-B, NEW YORK NY 10128
Lisa Nolan officer: Chief Business Officer 36 ROCKLAND MILLS, ROCKLAND DE 19732
Eliseo Oreste Salinas officer: President and CSO 7707 GATEWAY BLVD, NEWARK CA 94560